Adial Pharmaceuticals Files Prospectus Related To The Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders
-SEC Filing
Stocks · News reference
Adial Pharmaceuticals Says As Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting; Anticipates Matthew Davidson To Be Appointed President And CEO; Anticipates Termination Of CFO Vinay Shah After 2026 Annual Meeting; Anticipates Board Changes And Legacy Member Resignations
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As of August 10, 2026, Adial Pharmaceuticals, Inc. (the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ADIAL PHARMACEUTICALS, INC. (ADIL)
Filed: 2026-08-25 AccNo: 0001213900-26-093544 Size: 188 KB Item 3.02: Unregistered Sales of Equity Securities
Adial Pharmaceuticals shares are trading lower after the company reported a wider net loss for the second quarter.
Adial Pharmaceuticals Q2 EPS $(11.25)